Researchers have identified novel biomarkers for colorectal cancer, with one study highlighting FUT9 and MS4A3 as immune-phenotype and prognosis biomarkers. However, other reports suggest different biomarkers, such as CCR9 and CCL13, may be relevant in other types of cancer. The studies also explore the role of various genes and inflammatory signatures in cancer prognosis and treatment.